SCHEMBL5025239

SCHEMBL5025239

O=C(NOCc1c(Cl)cncc1Cl)c1cccc2oc3ccc(Cl)cc3c12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
AHR P35869 3/20 0.39
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAOB P27338 2/20 0.36
MAOA P21397 1/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
PDE4D Q08499 1/20 0.34
HSD17B10 Q99714 1/20 0.34
AURKB Q96GD4 1/20 0.34
TTR P02766 2/20 0.33
TP53 P04637 1/20 0.33
NQO1 P15559 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547458 0.90 NPC1 (0.36) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL5025403 0.90 NPC1 (0.34) NPC1RAB9AMAOBMAOALMNA
SCHEMBL4035701 0.82 LMNA (0.37) NPC1RAB9AALDH1A1MAOBMAOA
SCHEMBL5022725 0.78 NPC1 (0.47) NPC1RAB9AAHRHDAC8HDAC6
SCHEMBL6533419 0.74 BTK (0.38) NPC1RAB9AKDM4E
SCHEMBL5023305 0.73 GSTP1 (0.37) NPC1RAB9AHDAC8HDAC6ALDH1A1
SCHEMBL5016524 0.72 TDP1 (0.43) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL5018010 0.72 MAP2K1 (0.37) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL6532850 0.72 MEN1 (0.39) NPC1RAB9AALDH1A1KDM4EHTT
SCHEMBL5018082 0.72 NPC1 (0.44) NPC1RAB9AALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LTC4S, TSLP, GPR119 NPC1 853/4885RAB9A 3448/4885AHR 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.